Lanvis 40mg Tablet consists of the active ingredient as thioguanine. It is indicated to treat blood problems and cancers, namely acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL). Acute myelogenous leukemia is a rapidly progressing disorder that increases the number of white blood cells produced by the bone marrow. This can cause infections and bleeding. Acute lymphoblastic leukemia (ALL) refers to the accumulation of white blood cells that have not matured due to the abnormal production of white blood cells in the bone marrow. This condition is more prevalent among children aged below 5.

Lanvis 40mg Tablet in studies has also been shown to have a relatively low risk of causing nausea and vomiting compared to other chemotherapy drugs. Additionally, because it is taken orally, it may be more convenient for some patients than intravenous chemotherapy. Patients should also avoid consuming grapefruit or grapefruit juice while taking Lanvis 40mg Tablet, as it can interfere with the metabolism of the drug and increase the risk of side effects.

Lanvis 40mg Tablet uses in the treatment of the following:

• Acute lymphoblastic leukemia (ALL)
• Acute myelogenous leukemia (AML)

Lanvis 40mg Tablet is an antimetabolite medication that interferes with the DNA and RNA synthesis process in cancer cells, causing them to undergo programmed cell death, or apoptosis. By preventing the growth and spread of cancer cells, it can help to induce remission or prolong survival for patients with leukemia. This medicine is often used in combination with other chemotherapy drugs to increase its effectiveness.

Inform your healthcare provider about all your medicines, including prescription, over-the-counter, nutritional or vitamin supplements, and herbal products. Certain medications may interact with Lanvis 40mg Tablet and reduce effectiveness by causing undesirable side effects.

• Store at a cool temperature of 68°F and 77°F (20°C and 25°C).
• Protected from light.
• Keep it in its original packaging until it is ready to be used.
• Keep out of the reach of children and pets.
• Should be disposed of properly.

Lanvis 40mg Tablet is usually taken orally in the form of tablets. The tablets should be swallowed whole with water or another liquid, and should not be crushed, chewed, or broken. It is generally recommended to take it on an empty stomach, either one hour before or two hours after meals, to help maximize its absorption and effectiveness. Do not take a double dose to make up for a missed one.

Like all medications, Lanvis 40mg Tablet cause some side effects, although not every person who takes it will experience them. 

Serious:

• Unexpected bleeding or bruising
• Infections
• Yellow skin and eyes
• Liver toxicity
• Stevens-Johnson syndrome (life-threatening skin reaction)
• Tumor lysis syndrome (cancer cells release large amounts of toxins into the blood)

Common:

• Low number of blood cells and platelets
• Tiredness
• Nausea
• Pruritus
• Dark urine
• Rash
• Fever
• Vomiting
• Diarrhea
• Mouth ulcers
• Decreased kidney functions

If you are taking Lanvis 40mg Tablet, it is important to discuss any concerns with your healthcare provider. Patients with a history of allergy to this medication or any of these components should avoid taking it. Pregnant and breastfeeding women should be avoided while taking this medication. Women of reproductive potential should take contraceptives during and after several weeks of treatment. Patients should avoid the consumption of grapefruit during treatment. Falls and sharp cuts should be avoided as this medication increases the tendency of bleeding and raises the risk of infection. Always follow the dosing instructions and precautions provided by your doctor, and report any side effects or adverse reactions to your healthcare provider. Never stop or modify your medication regimen without consulting your healthcare provider.

1. Aspen Pharma Trading Limited, Electronic Medicines Compendium (EMC), [Revised on Sep 2017] [Accessed on 27th April 2023], https://www.medicines.org.uk/emc/files/pil.4654.pdf
2. H.G. Watson, J.I.O. Craig, L.M. Manson, Blood disease, Davidson’s Principles and Practice of Medicine, 22nd Edition, 2014, 989-1056.
3. Edward Chu, Cancer Chemotherapy, Lange’s Basic and Clinical Pharmacology, 14th Edition, 2018, 948-976
4. Apsen Global Inc, U.S Drud and Food Safety Administration (FDA), [Revised on May, 2018], [Accessed on 27th April 2023]https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/012429s028lbl.pdf